News

According to Neurocritical Care Society Guidelines, status epilepticus, which is classified as a single epileptic seizure lasting more than five minutes or two or more seizures within a

The interim analysis showed that BNT162b2 vaccine candidate is over 90% effective in preventing Covid-19 in participants without evidence of prior SARS-CoV-2 infection. BioNTech co-founder and CEO Ugur

The combination of Opdivo plus Yervoy with two cycles of chemotherapy is the first dual immunotherapy-based treatment option approved for patients in the European Union (EU) with this

Absorption Systems is a leading scientific, non-clinical CRO that provides pharmaceutical, biotech, medical device companies and regulatory agencies with research and testing for small and large molecules, cell

CAN-COVID is a randomised, double-blind and placebo-controlled study designed to evaluate the efficacy and safety of canakinumab plus standard of care (SoC) in hospitalised patients with Covid-19 pneumonia

Under this proposed CDLA agreement, Felix Biotechnology would obtain a worldwide license to TFF Pharmaceuticals’ Thin Film Freezing technology to develop and manufacture dry powder formulations of a

Based in San Diego, VelosBio is involved in the development of first-in-class cancer therapies targeting receptor tyrosine kinase-like orphan receptor 1 (ROR1). VLS-101, the company’s investigational antibody-drug conjugate

The single arm trial is evaluating up to 3 monthly injections of the investigational drug in patients scheduled for prostatectomy approximately 90 days after the first injection. Patients

Receiving ODD status from the FDA for the treatment of multiple myeloma is a critical next step for the development of XNK’s leading investigational drug candidate. XNK has